Health
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the results from its Phase 2a proof of concept study evaluating SGX945 (dusquetide) in the treatment of Behçet's Disease have been published in Rheumatology (Oxford), in an article entitled "Results from a Pilot Study of Dusquetide for the Treatment of Aphthous Ulcers
About this update from Soligenix, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Study results support advancing SGX945 in this difficult-to-treat orphan disease","length":80,"tagName":"p"}]},{"val":[{"type":"text","content":"Results suggest potential durability of response for maintenance therapy","length":72,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":152,"olType":false},{"type":"text","content":"PRINCETON, N.J., Dec. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the results from its Phase 2a proof of concept study evaluating SGX945 (dusquetide) in the treatment of Behçet's Disease have been published in Rheumatology (Oxford), in an article entitled "Results from a Pilot Study of Dusquetide for the Treatment of Aphthous Ulcers Associated with Behçet Syndrome".","length":599,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":321,"url":"https://media.zenfs.com/en/prnewswire.com/f8fb3c42c91dc54f57e9f93b36172fee"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ho.O3RK9q_NwN6W5xBdusA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTU2NjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/f8fb3c42c91dc54f57e9f93b36172fee","width":400,"height":321}},"href":"https://mma.prnewswire.com/media/2847851/SOLIGENIX_OUTCOMES.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The Phase 2a study, evaluating control of oral ulcers in Behçet's Disease, reported beneficial effects for 7 of 8 patients, over the 4 weeks of treatment as well as a potentially enduring effect through the 4 weeks of follow-up. Many Behçet's Disease treatments, including the most recently approved apremilast (Otezla®), do not have an enduring impact, necessitating frequent and continuous administration. Using the Phase 3 study of apremilast as a baseline for comparison, this open-label study indicated that the area under the curve (AUC; a composite measurement of both peak number of oral ulcers and the time to resolution of the oral ulcers), average number of oral ulcers, and improvements in oral pain for SGX945 were similar to outcomes obta...